Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
复制标题
DOI：
10.1016/j.ijcard.2016.11.302
复制
发表时间：
2017-01-15
影响因子：
3.5
通讯作者：
Seljeflot, Ingebjorg
中科院分区：
文献类型：
--
作者：
Chiva-Blanch, Gemma;Bratseth, Vibeke;Seljeflot, Ingebjorg
背景：循环微粒（cMPs）已被提议作为心血管疾病（CVD）的新生物标志物。我们的目的是研究cMPs与STEMI患者未来主要不良心血管事件（MACE）的预后相关性。方法：我们纳入了200例接受经皮冠状动脉介入治疗（PCI）的STEMI患者。在研究随访结束时（4.4（1.4）年），将100例具有主要复合终点（复发性非致死性急性MI、因心力衰竭再次住院、计划外PCI或因CV原因死亡）的患者与100例无主要终点的患者在性别、年龄和CVD风险因素方面进行病例匹配。cMPs从血管细胞进行了测量，通过流式细胞仪在平均28小时后发病symptoms.Results：没有差异，观察MP脱落患者或没有MACE在研究结束后的后续。然而，与随访期间存活的患者相比，因CV原因死亡的患者（n = 24）表现为总cMPs（膜联蛋白V-AV-+）、携带组织因子的cMPs增加，血小板、淋巴细胞、单核细胞和活化白细胞的MP脱落增加，左心室射血分数（LVEF）降低10%。ROC曲线分析显示，CD 14（+）/AV（+）、CD 11b（+）/CD 14（+）/AV（+）和CD 142（+）/CD 14（+）/AV（+）与LVEF联合检测对心血管死亡的预测效果最好。这些发现可能对STEMI患者的风险评估具有临床意义。(C)2016爱思唯尔爱尔兰有限公司版权所有。
Background: Circulating microparticles (cMPs) have been proposed as novel biomarkers of cardiovascular disease (CVD). We aimed to investigate the prognostic relevance of cMPs for futuremajor adverse cardiovascular events (MACE) in STEMI patients.Methods: We included 200 STEMI patients treated with percutaneous coronary intervention (PCI). One hundred patients with a primary composite end point (recurrent nonfatal acute MI, rehospitalization for heart failure, unscheduled PCI or death because of CV causes) were case-matched for sex, age, and CVD risk factors to 100 patients without a primary endpoint at the end of study follow-up (4.4 (1.4) years). cMPs from vascular cells were measured by flow cytometer at a mean of 28 h after onset of symptoms.Results: No differences were observed in MP shedding between patients with or without a MACE at the end of the study follow-up. However, compared to patients who survived during follow-up, patients who died because of CV causes (n = 24) presented with increased total cMPs (Annexin V-AV-+), cMPs carrying tissue factor, and increased MP shedding from platelets, lymphocytes, monocytes, and activated leukocytes, and similar to 10% lower left ventricular ejection fraction (LVEF). ROC-curve analyses showed that monocyte-derived cMPs (CD14(+)/AV(+), CD11b(+)/CD14(+)/AV(+) and CD142(+)/CD14(+)/AV(+)) considered together with LVEF best predicted cardiovascular mortality.Conclusions: Monocyte-derived cMPs assessed in the acute phase relate to the prognosis of CV death at the long term. These findings may be of clinical interest in the risk assessment of STEMI patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.